Analytical Data
-
Gene name
B3GAT1
- Application
-
Alternative Names
CD57; B3-GAT1; GLCATP; GlcAT-P; GlcUAT-P; HNK-1; LEU7; NK-1; Glucuronosyltransferase P; Galactosylgalactosylxylosylprotein 3-Beta-Glucuronosyltransferase 1
-
Species
Human
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q9P2W7
-
Expression Region
Thr28~Ile334
-
Molecular Weight
50kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
B3GAT1, or Beta-1,3-galactosyltransferase 1, is an essential enzyme involved in the glycosylation process, specifically in the synthesis of glycosaminoglycans such as hyaluronic acid and heparin sulfate. Understanding the functional role of B3GAT1 is crucial as it has implications in various biological processes, including cell signaling, embryonic development, and tissue repair. Dysregulation of B3GAT1 expression has been linked to several diseases, including congenital disorders and cancers, highlighting its potential as a therapeutic target. Research on the recombinant version of the B3GAT1 protein allows for the detailed study of its enzymatic activity, structure-function relationships, and interaction with substrates and regulatory proteins. Additionally, these studies can facilitate a better understanding of its role in the pathophysiology of diseases and contribute to the development of novel glycan-based biomaterials for biomedical applications. By producing and characterizing recombinant B3GAT1, scientists aim to unlock insights into its biochemical pathways, paving the way for innovative strategies in disease diagnosis and treatment.
